Cancer drug conjugates use new 'binding-to-release' strategy to bypass tumor resistance
A new drug-delivery strategy published in *Nature* on 26 August 2026 offers a potential leap forward in cancer treatment: instead of relying on cells to engulf and internally process drug-carrying antibodies, a chemical reaction triggered on the cell surface releases the therapeutic payload directly where it is needed The approach — termed "binding-to-release" (BTR) — could overcome a major bottleneck that has limited antibody–drug conjugates (ADCs) to a narrow subset of tumor targets.
By Source Reporters Newsdesk
Thu, 27 August 2026 · 2 min read
A new drug-delivery strategy published in *Nature* on 26 August 2026 offers a potential leap forward in cancer treatment: instead of relying on cells to engulf and internally process drug-carrying antibodies, a chemical reaction triggered on the cell surface releases the therapeutic payload directly where it is needed The approach — termed "binding-to-release" (BTR) — could overcome a major bottleneck that has limited antibody–drug conjugates (ADCs) to a narrow subset of tumor targets.
Traditional ADCs require tumor cells to internalize the antibody-drug complex and shuttle it through the lysosomal pathway before the cytotoxic payload is released. This process is inefficient, succeeding in only a fraction of internalized conjugates, and it restricts development to roughly 180 cell-surface proteins known to internalize reliably — a tiny slice of the more than 2,000 proteins in the human membrane proteome The field is therefore crowded around a handful of antigens such as HER2 and TROP2, leaving a vast landscape of potential targets — what researchers call an untapped "blue ocean" — effectively out of reach.
The new method, dubbed PhoPEx chemistry, triggers payload release through a reaction that occurs on the cell surface itself, eliminating the need for internalization. Using fibroblast activation protein (FAP) — a protein overexpressed on cancer-associated fibroblasts in many tumor types — as a model, the researchers showed that their BTR conjugates released their cytotoxic cargo without entering the cell. In mouse models, BTR-conjugated drugs dramatically reduced growth of FAP-positive tumors compared to controls, while sparing FAP-negative tumors, confirming that the approach is both potent and selectively targeted
The implications are twofold. First, the BTR strategy expands the universe of druggable targets from about 180 to thousands of potential cell-surface antigens. Second, by sidestepping the lysosomal bottleneck, the approach may lower the doses needed and reduce the intense competition among drug developers for the same few validated antigens. The ADC market — projected to reach US$26 billion — has been driven by clinical successes against HER2 and TROP2 cancers If the approach translates to human trials, it could unlock treatments for tumor types for which no targeted therapy currently exists.
**Sources:** Nature
Source Reporters corrects errors promptly. Spotted something wrong? Tell us — read our editorial standards and corrections policy.